Breakwell joins Beattie to lead healthcare assault

Former Edelman UK healthcare director and joint CEO Nigel Breakwell has re-emerged at Beattie Communications.

Beattie – which shifted its HQ from Falkirk, Scotland, to London last year – wants Breakwell to spearhead a charge for major pharma business from the capital. He has taken the title of director of healthcare.

Beattie is currently a littleknown name in healthcare comms. It scored its first business win for a major pharma firm 18 months ago, bagging a UK contract for GlaxoSmithKline's malaria drug Malarone.
It is also working on a hepatitis B vaccine for GSK and handles an account for high-street optician Specsavers.

Breakwell left Edelman in May (PRWeek, 27 May) and has since done consultancy work for Hill & Knowlton.

He said: 'My remit is to approach this as if I was setting up a new consultancy – this has given me a real buzz. We're planning for the next three to five years.'

Breakwell spent more than five years at Edelman, becoming joint CEO in October 2003. 'I enjoyed the joint CEO experience but I do get the biggest buzz from healthcare,' he said this week.

Prior to Edelman he was a healthcare director at Bell Pottinger and was briefly at Shire Hall. He has also held roles at Sanofi UK (sales) and at Merck Sharp & Dohme (external affairs).

Beattie made the symbolic move of relocating its HQ to London 12 months ago (PRWeek, 15 October 2004). The 100-strong firm now has around 30 staff in London, although its offices have
capacity for double that.

Explaining the move at the time, CEO Gordon Beattie said he was fed up that the firm was often referred to as 'that Scottish agency'.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in